Beijing Aosaikang Pharmaceutical Co., Ltd. (SHE:002755)

SHE:002755 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	1,126	1,411	1,047	772.71	1,166	1,369
Trading Asset Securities	1,156	683.28	713.83	839.08	522.39	100
Cash & Short-Term Investments	2,282	2,095	1,761	1,612	1,688	1,469
Cash Growth	20.45%	18.96%	9.25%	-4.51%	14.90%	14.14%
Accounts Receivable	266.86	231.83	181.24	323.03	581.86	968.27
Other Receivables	12.52	13.02	49.88	25.21	16.29	24.79
Receivables	279.39	244.85	231.12	348.23	598.15	993.06
Inventory	187.7	196.99	167.49	141.53	141.84	168.74
Other Current Assets	27.47	31.59	27	36.56	59.14	16.01
Total Current Assets	2,776	2,568	2,186	2,138	2,487	2,647
Property, Plant & Equipment	456.34	474.03	478.4	547.14	658.33	706.66
Long-Term Investments	117.93	118.72	118.21	107.57	105.18	77.36
Other Intangible Assets	511.69	146.34	98.34	95.77	97.69	84.91
Long-Term Deferred Tax Assets	24.86	24.62	25.73	25.85	28.69	26.9
Long-Term Deferred Charges	319.46	676.78	563.46	453.7	342.02	257.47
Other Long-Term Assets	42.24	38.97	53.26	46.22	5.75	7.89
Total Assets	4,249	4,048	3,524	3,414	3,725	3,808
Accounts Payable	59.63	59.98	38.29	39.08	65.72	95.29
Accrued Expenses	11.1	40.84	43.6	119.56	133.48	299.13
Short-Term Debt	47	62	114.02	45.03	-	20.01
Current Portion of Leases	3.53	4.06	3.03	3.45	2.61	-
Current Income Taxes Payable	11.5	2.05	3.59	2.13	7.54	13.14
Current Unearned Revenue	140.88	108.51	15.88	11.68	15.26	31.18
Other Current Liabilities	666.31	543.53	213.14	102.81	177.11	231.23
Total Current Liabilities	939.94	820.96	431.55	323.74	401.71	689.99
Long-Term Leases	4.29	6.62	6.75	8.92	11.52	-
Long-Term Unearned Revenue	62.23	60.66	64.72	55.81	68.93	69.41
Long-Term Deferred Tax Liabilities	17.15	17.15	10.18	12.56	15.08	15.49
Total Liabilities	1,024	905.39	513.2	401.03	497.24	774.89
Common Stock	928.16	928.16	928.16	928.16	928.16	928.16
Additional Paid-In Capital	162.86	136.94	136.94	50.73	0.94	1.49
Retained Earnings	2,043	1,989	1,828	1,977	2,295	2,101
Comprehensive Income & Other	10.67	8.95	6.58	7.25	-5.9	-3.7
Total Common Equity	3,145	3,063	2,900	2,963	3,219	3,027
Minority Interest	80.36	79.59	110.7	50.37	8.82	6.06
Shareholders' Equity	3,225	3,142	3,011	3,013	3,228	3,033
Total Liabilities & Equity	4,249	4,048	3,524	3,414	3,725	3,808
Total Debt	54.82	72.67	123.8	57.41	14.13	20.01
Net Cash (Debt)	2,227	2,022	1,637	1,554	1,674	1,449
Net Cash Growth	23.66%	23.52%	5.32%	-7.14%	15.51%	12.58%
Net Cash Per Share	2.45	2.14	1.76	1.65	1.81	1.57
Filing Date Shares Outstanding	928.16	928.16	928.16	928.16	928.16	928.16
Total Common Shares Outstanding	928.16	928.16	928.16	928.16	928.16	928.16
Working Capital	1,837	1,747	1,755	1,814	2,085	1,957
Book Value Per Share	3.39	3.30	3.12	3.19	3.47	3.26
Tangible Book Value	2,633	2,916	2,802	2,867	3,121	2,942
Tangible Book Value Per Share	2.84	3.14	3.02	3.09	3.36	3.17
Buildings	-	385.96	375.5	371.29	437.94	436.85
Machinery	-	804.36	744.21	767.2	776.51	764.36
Construction In Progress	-	23.51	36.07	29.8	19.71	15.72

Source: S&P Global Market Intelligence. Standard template. Financial Sources.